| PE TTM | 21.34Sector PE 37.88 |
|---|---|
| Market Cap | ₹224.8 CrMicro Cap |
| RSI | 52.16Neutral Zone |
| 1-Year Return | -13.8%Price change |
| Metric | Q2-27 | Q1-27 | Q2-26 |
|---|---|---|---|
| Revenue from Operations | 25.3 | 23.8 | 15.5 |
| Other Income | 0.1 | 0.2 | 0.2 |
| Total Income | 25.4 | 24.0 | 15.7 |
| Profit Before Tax | 5.5 | 3.3 | 2.2 |
| Net Profit | 4.1 | 2.5 | 1.6 |
| Operating Margin | 21.7% | 13.7% | 14.0% |
| Net Profit QoQ | +64.0% | ||
| Net Profit YoY | +156.2% | ||
| Adj. Profit QoQ | +74.2% | ||
| Adj. Profit YoY | +170.0% | ||
Key highlights
- Consolidated net profit reached ₹4.1 crore in Q2-27, rising 156.2% from ₹1.6 crore in Q2-26
- Revenue from operations grew to ₹25.3 crore, a significant increase over the ₹15.5 crore reported in the year-ago period
- Operating margins expanded to 21.7% from 14.0% YoY, reflecting improved operational efficiency
- Quarter-on-quarter profitability increased by 64.0% compared to the ₹2.5 crore net profit in Q1-27
- Total income for the quarter stood at ₹25.4 crore, supported by minimal other income of ₹0.1 crore
Consolidated Growth Driven by Pharmaceutical Demand
Sanjivani Paranteral Ltd reported a robust consolidated performance for Q2-27, with revenue from operations climbing to ₹25.3 crore from ₹15.5 crore in the same period last year. This growth follows the company's strategic expansion, including the September 2025 commissioning of the IV Fluid facility in Pune by its subsidiary, SPL Infusion Pvt. Ltd.
The consolidated net profit of ₹4.1 crore represents a substantial 156.2% year-on-year increase, significantly outperforming the broader pharmaceutical sector's average net profit growth of 0.6% for the same period. The quarterly profit also showed strong sequential momentum, rising 64.0% over the June quarter.
Operational Efficiency and Margin Expansion
- Operating margins improved to 21.7% in Q2-27, up from 14.0% in the prior year's corresponding quarter.
- The company reported a Profit Before Tax of ₹5.5 crore, more than doubling the ₹2.2 crore recorded in Q2-26.
- Other income remained low at ₹0.1 crore, indicating that profit growth is primarily driven by core manufacturing activities.
- Total expenditure for the six-month period ended September 2026 stood at ₹40.56 crore on a consolidated basis.
- The stock experienced a 5.45% day change following the result announcement, currently trading at a price of 183.
Strategic Pipeline and Market Positioning
The company continues to advance its CDMO order book, which targets a 20% annual growth rate. As of May 2026, Sanjivani Paranteral had 18 products in its regulatory approval pipeline, positioning it for potential volume increases in the coming quarters. With a TTM price-to-earnings ratio of 21.34x, the company is trading below the industry average PE of 37.96x.
Despite a 13.8% decline in stock price over the last year, the recent quarterly performance and stable promoter holding of 31.56% suggest a consolidation in its financial health within the mid-range performer category.
| Date | Announcement | Amount |
|---|---|---|
| 14 Aug 2026 | Q1 FY27 consolidated net profitSource: kotakneo.com | ₹2.49 Cr |
| 14 May 2026 | Q4 FY26 consolidated net profitSource: univest.in | ₹0.55 Cr |
| 13 Feb 2026 | Q3 FY26 consolidated net profitSource: economictimes.indiatimes.com | ₹2.78 Cr |
| 14 Nov 2025 | Q2 FY26 standalone net profitSource: stockscans.in | ₹1.64 Cr |
| 12 Aug 2025 | Q1 FY26 consolidated net profitSource: kotakneo.com | ₹1.73 Cr |
What to watch next
- Regulatory approval milestones for the 18 products currently in the pipeline as of May 2026
- Capacity utilization levels at the SPL Infusion Pvt. Ltd. facility in Pune throughout the second half of FY27
- Next quarterly earnings update scheduled for February 2027
| Share price | ₹183 |
|---|---|
| Market capitalisation | ₹224.80 Cr |
| Revenue (annual) | ₹68.67 Cr |
| Net profit (annual) | ₹6.79 Cr |
| Revenue (latest quarter) | ₹23.84 Cr+80.42% vs previous quarter |
| Net profit (latest quarter) | ₹2.41 Cr+242.63% vs previous quarter |
| P/E (TTM) | 21.34×Sector 37.88× |
| Promoter holding | 31.56%0.00% QoQ |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Quarterly and half-yearly financial results filing by Sanjivani Paranteral Ltd submitted to the BSE on November 5, 2026. Market figures from a third-party data provider.
